CTLA4 and melanoma: Preliminary evidence from the phase 1b Melanoma Intra-Tumoral Cavatak and Ipilimumab (MITCI) study showed that the combination of intratumoral V937 and the anti–CTLA-4 monoclonal antibody ipilimumab was not associated with any dose-limiting toxicities (DLTs) in 23 patients with stage IIIC to IVM1c melanoma [11].